Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Endocare/Aloka Ultrasound

This article was originally published in The Gray Sheet

Executive Summary

Endocare/Aloka Ultrasound: Firms enter strategic alliance for the U.S. marketing of Endocare's Cryocare cryotherapy system for treating prostate cancer. Under the agreement, Aloka will help train users of the Cryocare system in the proper use of ultrasound with cryotherapy. In exchange, Aloka gains rights to sell its ultrasound systems to Endocare's customer base. "Having the strength of a premier ultrasound company like Aloka helping us market cryotherapy will result in a more complete presentation to our customers," Endocare says. The Cryocare system, which uses an argon gas-based cryogen, was cleared by FDA in mid-1995 and formally introduced by Endocare at the recent American Urological Association annual meeting in Orlando...

You may also be interested in...

ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts